No description available.

A Doença de Alzheimer (DA) é o tipo mais comum de demência em idosos, a etiologia é multifatorial e a fisiopatologia da doença é complexa, com um novo caso acontecendo a cada sete segundos; globalmente, a doença está se tornando em uma lenta pandemia. Bioquimicamente, a DA é caracterizada pela presença das placas neuríticas (PNs) e os novelos neurofibrilares (NNFs). O peptídeo beta peptide1-42 (A?(1-42)) é o principal componente das placas neuríticas e tem sido fortemente associado ao estresse oxidativo, desregulação colinérgica e morte celular. Os múltiplos mecanismos envolvidos na patogênese criam consideráveis dificuldades para identificar alvos terapêuticos apropriados. As abordagens terapêuticas atuais melhoram temporariamente os sintomas da DA; no entanto, apesar de esforços intensivos, nenhum dos tratamentos disponíveis hoje conseguiu alterar o curso da doença. Porém, algumas das terapias mais relevantes para o tratamento da doença estão baseadas na atividade inibidora da acetilcolinesterase (AChE). Nos últimos anos, os alcaloides pertencentes à família Amaryllidaceae têm recebido muita atenção devido à atividade anticolinérgica e antioxidante. A galantamina foi o primeiro alcaloide isolado a partir de diferentes espécies de Amaryllidaceas e é o mais recente inibidor da AChE aprovado para o tratamento sintomático da DA. Este fato tem motivado a pesquisa de outros alcaloides como possíveis moduladores da doença em adição à atividade inibitória da AChE. Diante disso, o objetivo deste estudo foi investigar se o extrato de Caliphruria subedentata e a galantamina modulam a neurotoxicidade induzida pelo A?(1-42) na linhagem celular SH-SY5Y indiferenciada. Para compreender os mecanismos de neuroproteção, um conjunto de ensaios foi realizado tais como atividade inibitória da AChE, ensaios clonogênico, micronúcleos com bloqueio na citocinese celular (CBMNcyt), cometa; análises por microscopia eletrônica de transmissão (MET) e de metilação. Os resultados mostraram que tanto o extrato quanto a galantamina diminuíram significativamente a citotoxicidade e genotoxicidade induzida pelo A?(1-42). Além disso, ambos os tratamentos modularam alterações morfológicas mitocondriais induzidas pelo peptídeo. Em conclusão, os resultados deste estudo demonstraram que, em adição à atividade inibitória da AChE, tanto o extrato de C. subedentata quanto a galantamina exercem propriedades antigenotóxicas. Essas propriedades relevantes da Amaryllidaceaes e o fármaco tornam-se um potencial valioso para continuar sendo explorado. / Alzheimer´s disease (AD) is the most common type of dementia in elderly population, the etiology is multifactorial and the pathophysiology of the disease is complex, with a new case occurring every seven seconds; globally, the disease itself is becoming a slowly pandemic. Biochemically, the AD is characterized by presence of the neuritic plaques and neurofibrillary tangles. Amyloid beta peptide1-42 (A?(1-42)) is the principal component of neuritic plaques and it has been strongly associated with oxidative stress, cholinergic deregulation and cell death. The multiple mechanisms involved in the pathogenesis create considerable difficulty to identify appropriate targets. The current therapeutics approaches for AD improve temporally the symptoms; and despite intensive efforts, none of the treatments available today alter the course of disease. Nervertheless, some of the most relevant therapies for the treatment of disease are based on acetylcholinesterase (AChE) inhibitor activity. In recent years, alkaloids belonging Amaryllidaceae family have received great attention due to the well-known anticholinergic and antioxidant activity and the galanthamine was the first alkaloid isolated from different species of Amaryllidacea and it is the most recently AChE inhibitor approved for the symptomatic treatment of AD. This fact has motivated the screening of other alkaloids as possible modulators of disease in addition acetylcholinesterase activity. Purpose this study was to investigate whether C. subedentata extract and galanthamine modulate A?(1-42)- induced neurotoxicity in the undifferentiated SH-SY5Y cell line. To understand the mechanisms of the neuroprotection, a set of biomarkers such as AChE activity, clonogenic, cytokinesis block micronucleus cytome (CBMNcyt) and comet assays; beside transmission electron microscope (TEM) and methylation analyses were realized. The results showed that C. subedentata extract and galanthamine were capable to significantly reduce the A?(1-42)- induced cytotoxicity and genotoxicity. Furthermore both treatments modulated A?(1-42)- induced mitochondrial morphological alterations. In conclusion, this study demonstrated that in addition to inhibition of acetylcholinesterase (AChE), the extract of C. subedentata and galanthamine exert antigenotoxic properties. This relevant property of Amaryllidaceaes and galanthamine are worthwhile exploring further which may improve the development of new diseases-modifying agents.

<p>Heparan sulfate (HS) is a linear polysaccharide, located on the surface and in the extracellular matrix of most cells, that regulates functions of numerous proteins. HS-protein interaction is mainly mediated by sulfate groups found in N-sulfated (NS) regions of the HS, but may also involve rare HS substituents such as N-unsubstituted glucosamine (GlcNH₂) residues. The location of GlcNH₂ in an HS-epitope recognized by the monoclonal antibody 10E4, that specifically stains the prion lesions in scrapie-infected murine brain, suggests an involvement of GlcNH₂ in prion disease and other amyloid-related disorders. HS in general is strongly associated with amyloidosis, including Alzheimer’s disease (AD). Therefore, the aims of this thesis were to structurally characterize GlcNH₂-containing HS sequences found in native tissues, to further study HS epitopes recognized by 10E4, and to investigate the possible role(s) of GlcNH₂ and other HS structures in binding to amyloid β peptide (Aβ) (core material in AD plaque lesions, also stained by 10E4).</p><p>The GlcNH₂ content (0.7-4% of total disaccharide units) varied between HS from different tissues. Most GlcNH₂ units were found in poorly modified N-acetylated (NA-) or NA/NS-domains, located toward the polysaccharide-protein linkage region.</p><p>Binding of human cerebral cortex HS to Aβ(1–40) monomers requires N-, 2- and 6-O-sulfation of HS, while binding to Aβ fibrils requires N- and 2-O-sulfation only. GlcNH₂ units do not appreciably contribute to interaction with Aβ. Aβ fibril-binding HS domains also bind to fibroblast growth factor 2 (FGF-2), indicating that Aβ (neurotoxic) and FGF-2 (neuroprotective) may compete for common binding sites in HS. However, Aβ had no effect on FGF-2-induced MAPK signaling in NIH 3T3 fibroblasts.</p><p>Continued studies on 10E4-antigenic HS epitope(s) showed that binding of 10E4 to the previously identified antigenic tetrasaccharide, ∆UA-GlcNH₂-GlcA-GlcNAc, requires the nonreducing hexuronic acid (∆UA) to be 4,5 unsaturated (induced by lyase cleavage), and thus is artificial. Further studies are needed to clarify the potential involvement of GlcNH₂ in 10E4-recognition of the native HS epitope(s).</p>

Heparan sulfate (HS) is a linear polysaccharide, located on the surface and in the extracellular matrix of most cells, that regulates functions of numerous proteins. HS-protein interaction is mainly mediated by sulfate groups found in N-sulfated (NS) regions of the HS, but may also involve rare HS substituents such as N-unsubstituted glucosamine (GlcNH2) residues. The location of GlcNH2 in an HS-epitope recognized by the monoclonal antibody 10E4, that specifically stains the prion lesions in scrapie-infected murine brain, suggests an involvement of GlcNH2 in prion disease and other amyloid-related disorders. HS in general is strongly associated with amyloidosis, including Alzheimer’s disease (AD). Therefore, the aims of this thesis were to structurally characterize GlcNH2-containing HS sequences found in native tissues, to further study HS epitopes recognized by 10E4, and to investigate the possible role(s) of GlcNH2 and other HS structures in binding to amyloid β peptide (Aβ) (core material in AD plaque lesions, also stained by 10E4). The GlcNH2 content (0.7-4% of total disaccharide units) varied between HS from different tissues. Most GlcNH2 units were found in poorly modified N-acetylated (NA-) or NA/NS-domains, located toward the polysaccharide-protein linkage region. Binding of human cerebral cortex HS to Aβ(1–40) monomers requires N-, 2- and 6-O-sulfation of HS, while binding to Aβ fibrils requires N- and 2-O-sulfation only. GlcNH2 units do not appreciably contribute to interaction with Aβ. Aβ fibril-binding HS domains also bind to fibroblast growth factor 2 (FGF-2), indicating that Aβ (neurotoxic) and FGF-2 (neuroprotective) may compete for common binding sites in HS. However, Aβ had no effect on FGF-2-induced MAPK signaling in NIH 3T3 fibroblasts. Continued studies on 10E4-antigenic HS epitope(s) showed that binding of 10E4 to the previously identified antigenic tetrasaccharide, ∆UA-GlcNH2-GlcA-GlcNAc, requires the nonreducing hexuronic acid (∆UA) to be 4,5 unsaturated (induced by lyase cleavage), and thus is artificial. Further studies are needed to clarify the potential involvement of GlcNH2 in 10E4-recognition of the native HS epitope(s).

Interactions between peptides and biological lipid membranes play a crucial role in many cellular processes such as in the mechanism behind Alzheimer’s disease where amyloid-beta peptide (Abeta)is thought to be a key component. The initial step of binding between a surface active peptide and its target membrane or membrane receptor can involve a non specific electrostatic association where positively charged amino acid residues and a negatively charged membrane surface interact. Here, the use of high resolution MAS NMR provides a highly sensitive and non perturbing way of studying the electrostatic potential present at lipid membrane surfaces and the changes resulting from the association of peptides. The interaction between pharmacologically relevant peptides and lipid membranes can also involve incorporation of the peptide into the membrane core and by complementing the NMR approach with differential scanning calorimetry (DSC) the hydrophobic incorporation can be studied in a non invasive way. By using 14N MAS NMR on biological lipid systems for the first time, in addition to 31P, 2H NMR and differential scanning calorimetry (DSC), gives a full picture of the changes all along the phospholipid following interactions at the membrane interface region. Being able to monitor the full length of the phospholipid enables us to differentiate between interactions related to either membrane surface association or hydrophobic core incorporation. This approach was used to establish that the interaction between nociceptin and negatively charged lipid membranes is electrostatic and hence that nociceptin can initially associate with a membrane surface before binding to its receptor. Also, it was found that Abeta can interact with phospholipid membranes via two types of interactions with fundamentally adverse effects. The results reveal that Abeta can associate with the surface of a neuronal membrane promoting accelerated aggregation of the peptide leading to neuronal apoptotic cell death. Furthermore it is also shown that Abeta can anchor itself into the membrane and suppress the neurotoxic aggregation of Abeta.

A Doença de Alzheimer (DA) é o tipo mais comum de demência em idosos, a etiologia é multifatorial e a fisiopatologia da doença é complexa, com um novo caso acontecendo a cada sete segundos; globalmente, a doença está se tornando em uma lenta pandemia. Bioquimicamente, a DA é caracterizada pela presença das placas neuríticas (PNs) e os novelos neurofibrilares (NNFs). O peptídeo beta peptide1-42 (A?(1-42)) é o principal componente das placas neuríticas e tem sido fortemente associado ao estresse oxidativo, desregulação colinérgica e morte celular. Os múltiplos mecanismos envolvidos na patogênese criam consideráveis dificuldades para identificar alvos terapêuticos apropriados. As abordagens terapêuticas atuais melhoram temporariamente os sintomas da DA; no entanto, apesar de esforços intensivos, nenhum dos tratamentos disponíveis hoje conseguiu alterar o curso da doença. Porém, algumas das terapias mais relevantes para o tratamento da doença estão baseadas na atividade inibidora da acetilcolinesterase (AChE). Nos últimos anos, os alcaloides pertencentes à família Amaryllidaceae têm recebido muita atenção devido à atividade anticolinérgica e antioxidante. A galantamina foi o primeiro alcaloide isolado a partir de diferentes espécies de Amaryllidaceas e é o mais recente inibidor da AChE aprovado para o tratamento sintomático da DA. Este fato tem motivado a pesquisa de outros alcaloides como possíveis moduladores da doença em adição à atividade inibitória da AChE. Diante disso, o objetivo deste estudo foi investigar se o extrato de Caliphruria subedentata e a galantamina modulam a neurotoxicidade induzida pelo A?(1-42) na linhagem celular SH-SY5Y indiferenciada. Para compreender os mecanismos de neuroproteção, um conjunto de ensaios foi realizado tais como atividade inibitória da AChE, ensaios clonogênico, micronúcleos com bloqueio na citocinese celular (CBMNcyt), cometa; análises por microscopia eletrônica de transmissão (MET) e de metilação. Os resultados mostraram que tanto o extrato quanto a galantamina diminuíram significativamente a citotoxicidade e genotoxicidade induzida pelo A?(1-42). Além disso, ambos os tratamentos modularam alterações morfológicas mitocondriais induzidas pelo peptídeo. Em conclusão, os resultados deste estudo demonstraram que, em adição à atividade inibitória da AChE, tanto o extrato de C. subedentata quanto a galantamina exercem propriedades antigenotóxicas. Essas propriedades relevantes da Amaryllidaceaes e o fármaco tornam-se um potencial valioso para continuar sendo explorado. / Alzheimer´s disease (AD) is the most common type of dementia in elderly population, the etiology is multifactorial and the pathophysiology of the disease is complex, with a new case occurring every seven seconds; globally, the disease itself is becoming a slowly pandemic. Biochemically, the AD is characterized by presence of the neuritic plaques and neurofibrillary tangles. Amyloid beta peptide1-42 (A?(1-42)) is the principal component of neuritic plaques and it has been strongly associated with oxidative stress, cholinergic deregulation and cell death. The multiple mechanisms involved in the pathogenesis create considerable difficulty to identify appropriate targets. The current therapeutics approaches for AD improve temporally the symptoms; and despite intensive efforts, none of the treatments available today alter the course of disease. Nervertheless, some of the most relevant therapies for the treatment of disease are based on acetylcholinesterase (AChE) inhibitor activity. In recent years, alkaloids belonging Amaryllidaceae family have received great attention due to the well-known anticholinergic and antioxidant activity and the galanthamine was the first alkaloid isolated from different species of Amaryllidacea and it is the most recently AChE inhibitor approved for the symptomatic treatment of AD. This fact has motivated the screening of other alkaloids as possible modulators of disease in addition acetylcholinesterase activity. Purpose this study was to investigate whether C. subedentata extract and galanthamine modulate A?(1-42)- induced neurotoxicity in the undifferentiated SH-SY5Y cell line. To understand the mechanisms of the neuroprotection, a set of biomarkers such as AChE activity, clonogenic, cytokinesis block micronucleus cytome (CBMNcyt) and comet assays; beside transmission electron microscope (TEM) and methylation analyses were realized. The results showed that C. subedentata extract and galanthamine were capable to significantly reduce the A?(1-42)- induced cytotoxicity and genotoxicity. Furthermore both treatments modulated A?(1-42)- induced mitochondrial morphological alterations. In conclusion, this study demonstrated that in addition to inhibition of acetylcholinesterase (AChE), the extract of C. subedentata and galanthamine exert antigenotoxic properties. This relevant property of Amaryllidaceaes and galanthamine are worthwhile exploring further which may improve the development of new diseases-modifying agents.

Nitric oxide (NO) is a neurotransmitter involved in memory processes. Currently, the only recognized physiological signalling pathway controlled by NO is the activation of guanylyl cyclase. In this thesis, we propose an alternative NO-signalling pathway that involves the Heme-regulated eukaryotic initiation factor-2a kinase (HRI) and eIF2a phosphorylation. We have found that the enzyme BACE1, a key protein in Alzheimer’s disease (AD), is controlled by this novel pathway. This pathway would be involved in the physiology of memory formation and learning processes. We have also studied how an external stress factor, the Herpes Simplex Virus 1, can disrupt this cascade leading to a pathological increase in BACE1 and amyloid ß-peptide (Aß) production. Aß aggregates forming fibrils that generate free radicals. These react with NO producing peroxynitrite, which contribute to AD progression. Since NO turns toxic when produced in a pro-oxidant environment we have also studied the effect of peroxynitrite in Stroke. / L’òxid nítric (NO) és un neurotransmissor involucrat en processos de memòria. Actualment, l’única cascada de senyalització fisiològica controlada per NO consisteix en l’activació de la guanilat ciclasa. En aquesta tesi, en proposem una d’alternativa que inclou la fosforilació de eIF2a per la Heme-regulated eukaryotic initiation factor-2a kinase (HRI). Hem mostrat com l’enzim BACE1, una proteïna clau en la malaltia d’Alzheimer (AD), és controlat per aquesta nova cascada de senyalització, que podria estar involucrada en la fisiologia de l’aprenentatge i la memòria. També hem estudiat com un factor d’estrès extern, l’ Herpes Simplex Virus 1, pot pertorbar aquesta cascada donant lloc a increments patològics en BACE1 i pèptid ß-amiloide (Aß). L’Aß agrega formant fibril·les que generen radicals lliures. Aquests reaccionen químicament amb NO produint peroxinitrit, que contribueix a la progressió de l’AD. Pel fet que l’NO esdevé tòxic quan és produït en un entorn pro-oxidant, hem estudiat també l’impacte que el peroxinitrit té en l’ictus.

As the most prevalent cause of dementia worldwide, Alzheimer’s disease (AD) has become a global issue of public health. By current criteria, diagnosis of this neurodegenerative disorder requires both clinical confirmation of dementia and post-mortem detection of the so-called neurofibrillary tangles and senile plaques in the brain. Yet the main proteinaceous component of these plaques, the amyloid beta peptide (Abeta) is now widely believed to initiate a cascade of events that ultimately leads to Alzheimer’s disease. Besides, extensive evidence supports a pathogenic role of soluble oligomers formed upon Abeta aggregation in the onset of the disease, which, unlike Abeta fibrils, present distinct neurotoxic properties and correlate well with disease progression. Their detrimental effects have been suggested to appear decades before the first signs of cognitive impairment, making them biomarkers of choice in the study of the pathology. <p>Given that present guidelines for AD diagnosis are increasingly considered as ill-defined, reliable and early-stage detection methods taking into account the presence of toxic Abeta species are highly awaited by the medical community. In this regard, this thesis work describes the development of a sensing device aiming at the specific detection of the amyloid beta peptide in solution via recognition by antibodies grafted at the surface of functionalized germanium crystals. This new type of BIA-ATR (Biospecific Interaction Analysis - Attenuated Total Reflection) biosensor resorts on ATR-FTIR (Attenuated Total Reflection - Fourier Transform Infrared) spectroscopy, which is extremely sensitive to the secondary structure of proteins. The ATR mode uses germanium as optical transduction element combined to the evanescent wave principle to allow selective online monitoring of peptide-antibody binding events. <p>In the first part of this work, evaluation of the photochemistry on germanium optical elements have been the subject of intense research focus. Our investigations led to the elaboration of a quality control of functionalization efficiency based on infrared spectroscopy. We also set up in the lab an original ELISA method for selecting antibodies in terms of their true affinity for the Abeta peptide. <p>Thereafter binding experiments were carried out on the BIA-ATR sensor using different antibodies and Abeta isoforms, leading to the establishing of a standardized protocol for the detection of molecules of interest. Our results showed that Abeta detected on the biosensor corresponded precisely to antibody-bound peptide, whereas Abeta assemblies, and especially Abeta 1-42 oligomeric conformations, could be discriminated with respect to their spectral signature. This point, which was later confirmed by unsupervised statistical analysis, could be considered as particularly interesting and innovative, since to our knowledge, such conformation-sensitivity has never been observed with existing AD diagnostic methods. Moreover, effective recycling of the functionalized crystals has been demonstrated, which confers thereby a second major advantage to the biosensor. <p>In parallel to these experiments, a structural characterization study of Abeta species was undertaken in order to generate a database of IR spectra, as reference for future comparative analysis of physiological fluids on the biosensor. ATR-FTIR measurements revealed a strong dependency on the ratio between oligomers and fibrils within a mixture and their relative ratio in antiparallel and parallel beta-sheet content. Interestingly, separation trials of oligomeric entities demonstrated a specific effect of Cu2+ ions on Abeta aggregation. Stabilization of small oligomeric aggregates at equimolar Cu2+:Abeta ratios, which had never been clearly evidenced so far, could help to unravel some aspects of the complex role of copper in AD development. <p>These investigations illustrate the applicability of the so-called BIA-ATR methodology to online detection of different forms of the Abeta peptide in solution and the potential of this new sensor technology to fulfill current pitfalls in providing a reliable and comprehensive approach of AD diagnosis. / Doctorat en Sciences agronomiques et ingénierie biologique / info:eu-repo/semantics/nonPublished

La maladie d'Alzheimer (MA) est caractérisée par un déclin progressif des fonctions cognitives avec une détérioration de la mémoire, une atrophie cérébrale et deux lésions histologiques caractéristiques retrouvées lors d'examens post-mortem : les plaques extracellulaires de peptide β-amyloïde et les enchevêtrements intracellulaires de la protéine Tau anormalement phosphorylée. De nombreux modèles animaux de la MA ont été développés afin de comprendre et de tester différents traitements dirigés contre cette pathologie. Cependant, aucun modèle de rongeur non transgénique, développant à la fois les plaques amyloïdes et la pathologie neurofibrillaire, n'est disponible à ce jour. L'objectif de cette étude est de développer le premier modèle non transgénique, développant les deux lésions histologiques caractéristiques de la MA chez le rat. Le principe consiste à réaliser une injection concomitante et intrahippocampale d'un AAV (virus associé aux adénovirus) recombinant contenant le gène humain de la protéine Tau présentant la mutation P301L, et du peptide Aβ1-42 qui est le principal composant des plaques amyloïdes. Après plusieurs expériences, nous avons obtenu un modèle animal représentatif des stades précoces de la MA, c'est-à-dire avec des lésions focalisées dans l'une des premières structures du cerveau affectée par la MA : l'hippocampe. La présence des deux lésions histopathologiques caractéristiques de la maladie, accompagnée d'une astrocytose, a été observée par immunohistofluorescence. Une détérioration de la mémoire concernant plus particulièrement la mémoire de travail, ainsi que des anormalités de l'activité électrique cérébrale et notamment durant les phases de sommeil paradoxal, enregistrées par électroencéphalographie, ont également été mises en évidence. / Alzheimer's disease (AD) is characterized by a progressive decline in cognitive function with a memory impairment, a brain atrophy, and two histological hallmarks observed from post-mortem examination: extracellular β-amyloid plaques and intracellular tangles of the Tau protein abnormally phosphorylated. Numerous animal models of AD have been developed to understand and to test drugs against this pathology. However, any non-transgenic model of rodent developing amyloid plaques and the neurofibrilary pathology is currently available. The aim of this study is to develop the first non-transgenic model producing the two histopathological features of AD in the rat. The principle is to perform a concomitant intrahippocampal injection of a recombinant AAV (Adeno-Associated Virus) containing the human transgene tau with the P301L mutation, and of Aβ1-42 peptide, the main component of the amyloid plaques. After several experiments, we have obtained an animal model representative of the early steps of AD, i.e. with lesions focalized in one of the first affected brain structures in the AD: the hippocampus. The presence of the two histopathological hallmarks has been observed by immunohistofluorescence and associated with an astrogliosis. A memory impairment concerning more particulary the working memory, and abnormalities of the electrical activity of the brain and of the rapid eye movement sleep recorded by electroencephalography, are also characterized.

La matrice extracellulaire est composée d’environ 300 protéines et protéoglycanes qui constituent le matrisome et de 800 protéines associées (Naba et al., 2012a) et glycosaminoglycanes. C’est un protéome sous-exploré qui est modifié dans de nombreuses pathologies. Les fragments bioactifs issus de la matrice extracellulaire (matricryptines) sont capables de réguler des processus physiopathologiques et notamment l’angiogenèse et les pathologies cérébrales (Ricard-Blum and Salza, 2014). Environ 90 % des patients atteints de la maladie d’Alzheimer (MA) ont une angiopathie amyloïde cérébrale. L’angiogenèse contribue au déroulement de la MA. Nous nous sommes intéressés à l’endostatine (ES), une matricryptine du collagène XVIII qui possède des activités anti-angiogéniques, anti-tumorales et est également présente dans les plaques amyloïdes chez les patients atteints de la MA. Elle est libérée par les neurones et est capable de former des fibrilles amyloïdes in vitro (Kranenburg et al., 2003). Elle pourrait donc avoir une implication dans la MA. Nous avons montré que l'ES est présente dans le liquide céphalorachidien et que le rapport de sa concentration à celle des marqueurs classiques de la MA permet d’améliorer le diagnostic des patients atteint de démence fronto-temporale (DFT) et de discriminer les patients atteints de MA de ceux atteint de DFT et de pathologie nonMA/nonDFT. Nous avons établi les répertoires d’interactions extracellulaire du peptide -amyloïde (1-42) sous formes monomérique, oligomérique, fibrillaire ou agrégée et montré que l’oligomérisation et la fibrillogenèse augmentent la capacité d’interaction du peptide -amyloïde. Nous avons établi le réseau d’interaction global de l’endostatine par résonance plasmonique de surface en mode imagerie et identifiés 21 nouveaux partenaires de cette matricryptine. Nous avons plus particulièrement caractérisé son interaction avec la Procollagen C-Proteinase Enhancer-1, une protéine dont nous avons montré qu’elle donne naissance à une matricryptine anti-angiogénique. Nous avons enfin construit les réseaux d’interactions extracellulaires spécifiques de l’angiogenèse et de la maladie d’Alzheimer et des processus amyloïdes pour identifier les protéines connectant ces deux processus qui sont des cibles thérapeutiques potentielles. Ces réseaux d’interactions ont été créés à l’aide de 239 interactions que nous avons identifiées expérimentalement et des interactions décrites dans la littérature. Ces données seront à terme disponibles dans la base de données spécifique des interactions extracellulaires créée au laboratoire, MatrixDB, dans la nouvelle version à laquelle nous avons contribué. / The extracellular matrix include approximately 300 proteins and proteoglycans which constitute the matrisome and 800 associated proteins (Naba et al., 2012a) and glycosaminoglycans. It is an under-explored proteome which is modified in many diseases. Extracellular matrix bioactives fragments (matricryptins) are able to regulate physiopathological process like angiogenesis and cerebral disorders (Ricard-Blum and Salza, 2014). About 90 % of patients with Alzheimer's disease (AD) have cerebral amyloid angiopathy. Angiogenesis contributes to the development of AD. We are studying endostatin (ES), a matricryptin of collagen XVIII which has anti-angiogenic and anti-tumoral activities and is also present in amyloid plaques in AD patients. ES is released by neurons and is able to form amyloid fibrils in vitro (Kranenburg et al., 2003). This anti-angiogenic matricryptin could therefore be involved in AD. We have shown that ES is present in the cerebrospinal fluid of AD patients and the ratio of its concentrations to conventional markers of AD improves the diagnosis of patients with frontotemporal dementia (FTD) and discriminate AD patients from those suffering from FTD and pathology noAD/noDFT. We have established the extracellular interactions repertoires of the -amyloid peptide (1-42) in monomeric, oligomeric, fibrillar or aggregated forms and showed that the oligomerization and fibrillogenesis increase the interaction capacity of the -amyloid peptide. We have established the global interaction network of endostatin by surface plasmon resonance imaging and identified 21 new partners of this matricryptin. Specifically, we characterized its interaction with the Procollagen C-Proteinase Enhancer-1, a protein which gives rise to an anti-angiogenic matricryptin. We finally built networks of specific extracellular interactions of angiogenesis and of Alzheimer's disease and amyloid process to identify proteins connecting these two processes that are potential therapeutic targets. These interaction networks have been built using 239 interactions including those we have identified experimentally and those described in the literature. This data will be available in the database specific of extracellular interactions created in the laboratory, MatrixDB, in the new version of which we contributed.